169 related articles for article (PubMed ID: 35651416)
1. New-Onset Autoimmune Diabetes Mellitus Presenting As Diabetic Ketoacidosis in Association With Pembrolizumab Therapy and Long Term Follow-Up: Case Report.
Pachpande V; Mullangi S; Lekkala MR; Patel A
Cureus; 2022 Apr; 14(4):e24479. PubMed ID: 35651416
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
3. New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer.
Cunha C; Silva E; Vieira AC; Saraiva C; Duarte S
Endocrinol Diabetes Metab Case Rep; 2022 Feb; 2022():. PubMed ID: 35140188
[TBL] [Abstract][Full Text] [Related]
4. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
Kedzior SK; Jacknin G; Hudler A; Mueller SW; Kiser TH
Am J Case Rep; 2021 Jun; 22():e931702. PubMed ID: 34185763
[TBL] [Abstract][Full Text] [Related]
5. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
Hakami OA; Ioana J; Ahmad S; Tun TK; Sreenan S; McDermott JH
Endocrinol Diabetes Metab Case Rep; 2019 Mar; 2019():. PubMed ID: 30836329
[TBL] [Abstract][Full Text] [Related]
6. Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report.
Lopes AR; Russo A; Li AY; McCusker MG; Kroopnick JM; Scilla K; Mehra R; Rolfo C
Transl Lung Cancer Res; 2020 Oct; 9(5):2149-2156. PubMed ID: 33209634
[TBL] [Abstract][Full Text] [Related]
7. A Case of Pembrolizumab-Induced Diabetic Ketoacidosis and Hyperthyroidism in a Patient With Recurrent Esophageal Adenocarcinoma.
Salangsang J; Sapkota S; Kharel S; Gupta P; Kalla A
Cureus; 2023 Feb; 15(2):e35276. PubMed ID: 36825072
[TBL] [Abstract][Full Text] [Related]
8. [IMMUNE CHECKPOINT INHIBITOR-INDUCED DIABETES MELLITUS].
Fischer M; Amos S; Levy L; Pollack R
Harefuah; 2021 Oct; 160(10):657-662. PubMed ID: 34689435
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
Li S; Zhang Y; Sun Z; Hu J; Fang C
Medicine (Baltimore); 2018 Nov; 97(45):e12907. PubMed ID: 30407284
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab-Induced Diabetic Ketoacidosis: A Review of Critical Care Case.
Sankar K; Macfarlane M; Cooper O; Falk J
Cureus; 2021 Oct; 13(10):e18983. PubMed ID: 34820238
[TBL] [Abstract][Full Text] [Related]
11. Diabetic Ketoacidosis Secondary to New Onset Type 1 Diabetes Mellitus Related to Pembrolizumab Therapy.
Hernandez A; Zeidan B; Desai P; Frunzi J
Cureus; 2021 Feb; 13(2):e13302. PubMed ID: 33738153
[TBL] [Abstract][Full Text] [Related]
12. Late-onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer.
Ichihara S; Kunishige M; Kadota N; Okano Y; Machida H; Hatakeyama N; Naruse K; Shinohara T; Takeuchi E
Thorac Cancer; 2023 Jan; 14(1):81-84. PubMed ID: 36411591
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune diabetes from pembrolizumab: A case report and review of literature.
Bhanderi H; Khalid F; Bodla ZH; Muhammad T; Du D; Meghal T
World J Clin Oncol; 2023 Nov; 14(11):535-543. PubMed ID: 38059185
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab.
Zand Irani A; Almuwais A; Gibbons H
BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35039353
[TBL] [Abstract][Full Text] [Related]
15. A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma.
Wu L; Li B
Diabetes Metab Syndr Obes; 2021; 14():753-757. PubMed ID: 33628041
[TBL] [Abstract][Full Text] [Related]
16. Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus.
Wei HH; Lai YC; Lin G; Lin CW; Chang YC; Chang JW; Liou MJ; Chen IW
Diabetol Metab Syndr; 2024 Jan; 16(1):26. PubMed ID: 38254155
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma.
Kichloo A; Albosta MS; McMahon S; Movsesian K; Wani F; Jamal SM; Aljadah M; Singh J
J Investig Med High Impact Case Rep; 2020; 8():2324709620951339. PubMed ID: 32830561
[TBL] [Abstract][Full Text] [Related]
18. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience.
Byun DJ; Braunstein R; Flynn J; Zheng J; Lefkowitz RA; Kanbour S; Girotra M
Diabetes Care; 2020 Dec; 43(12):3106-3109. PubMed ID: 33051330
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
de Filette JMK; Pen JJ; Decoster L; Vissers T; Bravenboer B; Van der Auwera BJ; Gorus FK; Roep BO; Aspeslagh S; Neyns B; Velkeniers B; Kharagjitsingh AV
Eur J Endocrinol; 2019 Sep; 181(3):363-374. PubMed ID: 31330498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
